Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Inferior Vena Cava
Verified date | August 2019 |
Source | National Taiwan University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Liver cancer including primary hepatocellular carcinoma (HCC) and metastatic liver cancers is one the most common malignancies in the world. Over 10000 new cases per year are diagnosed in Taiwan. Several pre-clinical studies have already demonstrated microwave ablation (MWA) is a safe and effective treatment for live cancers. The system (Solero Microwave Tissue Ablation System) with 2.45 GHz microwave generator could create a spherical ablation zone, and has certificated by CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval in 2017. However, there are still few experiences in using MWA for tumor ablation in Taiwan. In this study, the researchers will perform MWA for 20 inoperable patients with liver cancers adjacent to inferior vena cava (IVC). The researchers will appraisal the clinical feasibility and advantage of the system by this study.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 22, 2020 |
Est. primary completion date | January 6, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Patients must meet all of the following inclusion criteria to be eligible for this study: 1. The diagnosis of hepatocellular carcinoma (HCC) or metastatic liver cancers with pathologic proven, and the diagnosis of HCC will be made by pathology / cytology or according to the AASLD(2010) diagnostic criteria. In brief, Nodules larger than 1 cm found on ultrasound screening of a cirrhotic liver should be investigated further with either tri-phase multidetector CT scan or dynamic contrast enhanced MRI. If the appearances are typical of HCC (i.e., hypervascular in the arterial phase with washout in the portal venous or delayed phase), the lesion should be treated as HCC. If the findings are not characteristic or the vascular profile is not typical, a second contrast enhanced study with the other imaging modality should be performed, or the lesion should be biopsied. Biopsies of small lesions should be evaluated by expert pathologists. Tissue that is not clearly HCC should be stained with all the available markers including CD34, CK7, glypican 3, HSP-70, and glutamine synthetase to improve diagnostic accuracy. 2. Unsuitable for surgical resection but local ablation is indicated, however, the distance between tumour and inferior vena cava is smaller than 1 cm. 3. Have at least one, but less than or equal to 3 tumors, 4. Each tumor must be = 5 cm in diameter, 5. Child-Pugh class A-B, 6. Eastern Cooperative Oncology Group (ECOG) score of 0-1, 7. American Society of Anaesthesiologists (ASA) score = 3, 8. Adequate bone marrow and liver function (1). Platelet count = 100 K/?l(2). Total bilirubin ? 3 mg/dL(3). ALT and AST < 5 x upper limit of normal (4). PT-INR ? 2.0. 9. The disease status is not suitable to receive transarterial chemoembolization or other standard treatment. 10. Prior Informed Consent Form 11. Life expectancy of at least 3 months. Exclusion criteria Patients presenting with any of the following will not be enrolled into this study: 1. Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception, 2. Received treatment with an investigational agent/ procedure within 30 days prior to microwave ablation 3. Patients who cannot tolerate RFA procedure, including the patients have tumors closed to gall bladder, pancreas, liver hilum and main bile ducts 4. Acute infection or inflammation, acute and severe dysfunction of heart, liver and kidney, and the patients with metallic implantation including pacemaker. 5. Known history of HIV infection 6. Concurrent extrahepatic cancer |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei | Test2 |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the efficacy of microwave ablation for the treatment of primary or secondary liver cancers: modified RECIST criteria | The primary measure for this will be the evaluation of tumor response according to the modified RECIST criteria by CT or MR imaging performed 1 month after treatment. | up to one year | |
Secondary | safety and local tumor recurrences | The safety endpoint will be treatment-related Serious Adverse Events occurring within 30 days of treatment. | within 30 days of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03007212 -
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
|
Phase 4 | |
Terminated |
NCT03236649 -
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
|
Phase 3 | |
Recruiting |
NCT04687969 -
Multimodal Machine Learning Characterization of Solid Tumors
|
||
Completed |
NCT02562755 -
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
|
Phase 3 | |
Withdrawn |
NCT02406508 -
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
|
Phase 2 | |
Completed |
NCT01972672 -
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT01247298 -
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
|
Phase 0 | |
Completed |
NCT03735628 -
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02188901 -
Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study
|
N/A | |
Active, not recruiting |
NCT04522908 -
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
|
Phase 2 | |
Terminated |
NCT01433016 -
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
|
Phase 2 | |
Withdrawn |
NCT04465734 -
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
|
Phase 3 | |
Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03753659 -
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT01821482 -
A Study of DC-CIK to Treat Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT03516071 -
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
|
Phase 2 | |
Completed |
NCT01761266 -
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
|
Phase 3 | |
Not yet recruiting |
NCT06345001 -
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer
|
Phase 1 | |
Completed |
NCT02794805 -
Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis
|
Phase 2 |